Infringement Order Blocks Viatris’ US Symbicort Rival Until July 2023
Viatris Believes It Could Lose FDA Approval For Breyna Generic
After a string of victories, Viatris has fallen to AstraZeneca’s US Symbicort intellectual property, pushing back its planned generic launch by half a year.
